A validated high-performance liquid chromatographic method for the determination of moclobemide and its two metabolites in human plasma and application to pharmacokinetic studies

Column Selection for Biomedical Analysis Supported by Column Classification Based on Four Test Parameters

This article focuses on correlating the column classification obtained from the method created at the Katholieke Universiteit Leuven (KUL), with the chromatographic resolution attained in biomedical separation. In the KUL system, each column is described with four parameters, which enables estimation of the F_KUL value characterising similarity of those parameters to the selected reference stationary phase. Thus, a ranking list based on the F_KUL value can be calculated for the chosen reference column, then correlated with the results of the column performance test. In this study, the column performance test was based on analysis of moclobemide and its two metabolites in human plasma by liquid chromatography (LC), using 18 columns. The comparative study was performed using traditional correlation of the F_KUL values with the retention parameters of the analytes describing the column performance test. In order to deepen the comparative assessment of both data sets, factor analysis (FA) was also used. The obtained results indicated that the stationary phase classes, closely related according to the KUL method, yielded comparable separation for the target substances. Therefore, the column ranking system based on the F_KUL-values could be considered supportive in the choice of the appropriate column for biomedical analysis.

Identification of RC-33 as a potent and selective σ1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-scale synthesis, physicochemical characterization and in vitro metabolic stability

Strong pharmacological evidences indicate that σ1 receptors are implicated in the pathophysiology of all major CNS disorders. In the last years our research group has conducted extensive studies aimed at discovering novel σ1 ligands and we recently selected (R/S)-RC-33 as a novel potent and selective σ1 receptor agonist. As continuation of our work in this field, here we report our efforts in the development of this new σ1 receptor agonist. Initially, we investigated the binding of (R) and (S) enantiomers of RC-33 to the σ1 receptor by in silico experiments. The close values of the predicted affinity of (R)-RC-33 and (S)-RC-33 for the protein evidenced the non-stereoselective binding of RC-33 to the σ1 receptor; this, in turn, supported further development and characterization of RC-33 in its racemic form. Subsequently, we set-up a scaled-up, optimized synthesis of (R/S)-RC-33 along with some compound characterization data (e.g., solubility in different media and solid state characterization by thermal analysis techniques). Finally, metabolic studies of RC-33 in different biological matrices (e.g., plasma, blood, and hepatic S9 fraction) of different species (e.g., rat, mouse, dog, and human) were performed. (R/S)-RC-33 is generally stable in all examined biological matrices, with the only exception of rat and human liver S9 fractions in the presence of NADPH. In such conditions, the compound is subjected to a relevant oxidative metabolism, with a degradation of approximately 65% in rat and 69% in human. Taken together, our results demonstrated that (R/S)-RC-33 is a highly potent, selective, metabolically stable σ1 agonist, a promising novel neuroprotective drug candidate.

Electrochemical behavior of Moclobemide at mercury and glassy carbon electrodes and voltammetric methods for its determination

Electrochemical oxidation and reduction properties of Moclobemide (MCB) were investigated at glassy carbon electrode (GCE) and hanging mercury drop electrode (HMDE). Diffusion-adsorption behavior and some extra electrochemical parameters such as diffusion coefficient, number of transferred electrons and proton participated to its electrode mechanisms on both electrode and surface coverage coefficient were calculated from the results of cyclic voltammetry and square-wave voltammetry. Reversible catalytic hydrogen wave mechanism was proposed at HMDE and single two-electron/two-proton irreversible oxidation mechanism controlled by adsorption with some diffusion contribution at GCE was proposed. Experimental parameters were optimized to develop new, accurate, rapid, selective and simple voltammetric methods for direct determination of MCB in pharmaceutical dosage forms and spiked human serum samples without time-consuming steps prior to drug assay. In these methods, the lowest limit of detection (LLOD) was found to be 0.0235 μM. Methods were successfully applied to determine the MCB content of commercial pharmaceutical preparations and spiked human urine. The methods were found to be highly accurate and precise.